Redeye offers a preview of Polygien's Q4 results set to be released on February 13.
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered a SEK30.
We estimate 2024 net profit of DKK 310m, at the upper end of the recently updated 2024 guidance rang...
Ahead of Atria’s Q4 report, we maintain our estimates intact.
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes ...
With the directed issue of units amounting to SEK 35m, supplemented by SEK 20m in loans, Nanexa secu...
Exposure to fast-growing and non-cyclical infrastructure We forecast 23% EBITA CAGR in '23-'26e, ~40...
Neovici AB (”Neovici” eller ”Bolaget”) är ett snabbväxande SaaS-bolag inom fintech som har utvecklat...
Redeye comments on Freemelt’s preliminary Q4 figures, which came in stronger than expected in terms ...
Announces some preliminary Q4 figures due to rights issue Sales SEK 8.
Ahead of NoHo's Q4 2024 report, due out 12 February, we tweak our estimates.
Redeye provides its comment on the news of the severe adverse event that occurred in the use of off-...
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det största avtalet i bolagets his...
With the release of a Preliminary Economic Assessment (PEA) for the restart of the Sydvaranger mine,...
Q4e: sales of SEK 42m, adj. EBIT of SEK 11m '24e-'26e sales up by 1-5% Q4 EBIT should be diluted sli...
Ahead of Relais' Q4 report, we take a slightly more cautious view on Q4 margins given the warm winte...
De underliggande portföljbolagen fortsätter att utvecklas väl och väntas växa omsättning respektive ...
Q4 due Thursday, 6 February We expect strong order intake on pent-up demand We increase '25e-'26e EP...
Q3 figures below due to maintenance on Brage Løvmeis plugged and abandoned, Bounty next We reiterate...
On January 22nd, STENOCARE announced the outcome of the conditional rights issue, which was subscrib...
